The insula mediates the effects of glucocorticoids in anxiety

Bahamonde, Tamara; Quintana-Donoso, Daisy; Linsambarth, Sergio; Jerez-Baraona, Juan Manuel; Pena, Francisca; Tamburini, Giovanni; Verdugo, Daniel Antonio; Lemunao-Inostroza, Yordan; Ogaz, Francisco; Diaz-Galarce, Raul; Rojas, Sebastian; Stehberg, Jimmy

Abstract

Increased activity in the insula has been consistently reported to be associated with anxiety and anxiety-related disorders. However, little is known on how the insula regulates anxiety. The present study aims at determining the role of the insula on the effects of glucocorticoids in anxiety. A combination of pharmacological manipulations, including blockade of adrenal GC synthesis by metyrapone and intra-insular microinjections of corticosterone, corticosterone-BSA, mineralocorticoid receptor (MR) antagonist spironolactone and glucocorticoid receptor (GR) antagonist mifepristone, were used to assess the short-term (5 min) effects of intra-insular corticosterone in two anxiety-like behaviors in male Sprague-Dawley rats. The elevated plus maze (EPM) and Novelty Suppressed Feeding (hyponeophagia) were utilized. We found that corticosterone in the insula is sufficient to prevent the anxiolytic effects corticosterone synthesis blockade in anxiety, and that intra-insular corticosterone has anxiolytic or anxiogenic effects depending on the amount of corticosterone microinjected and the arousal associated to the test, without affecting the HPA axis. Glucocorticoid anxiolytic effects in the insula are mediated by MRs, while its anxiogenic effects are dependent on a mifepristone-sensitive membrane-bound mechanism. Anxiety appears to be modulated at the insula through a competition between fast MR-dependent anxiolytic and membrane-associated anxiogenic signaling pathways that orchestrate the behavioral response to stress and determines the resulting level of anxiety.

Más información

Título según WOS: ID WOS:001029132800001 Not found in local WOS DB
Título de la Revista: NEUROPHARMACOLOGY
Volumen: 237
Editorial: PERGAMON-ELSEVIER SCIENCE LTD
Fecha de publicación: 2023
DOI:

10.1016/j.neuropharm.2023.109620

Notas: ISI